These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine]. Sigwald J; Raymondeaud C; Piot C Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718 [No Abstract] [Full Text] [Related]
25. [Study of L-dopa treatment and its principal side effects in aged subjects]. Antonini F; Baroni A; Bucalossi A; Roveyaz L Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357 [No Abstract] [Full Text] [Related]
26. [L-dopa treatment of persons with parkinsonism in a hospital for geriatric rehabilitation]. Antonini F; Baroni A; Roveyaz L Sist Nerv; 1970; 22(2):74-81. PubMed ID: 5504560 [No Abstract] [Full Text] [Related]
27. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism]. Gerstenbrand F; Grünberger J; Schubert H Nervenarzt; 1973 Aug; 44(8):428-33. PubMed ID: 4733895 [No Abstract] [Full Text] [Related]
28. [Treatment of parkinsonism with the drug L-DOPA]. Stoliarova LG; Kistenev BA Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):199-205. PubMed ID: 4795170 [No Abstract] [Full Text] [Related]
29. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
31. [Use of L-DOPA in the therapy of parkinsonism]. D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734 [No Abstract] [Full Text] [Related]
32. Abnormal mouth-movements and oral damage associated with L-DOPA treatment. Sacks OW; Ross SJ; DePaola DP; Kohl MS Ann Dent; 1970; 29(4):130-44. PubMed ID: 5275661 [No Abstract] [Full Text] [Related]
33. L-Dopa in the treatment of parkinsonism. Calne DB Clin Pharmacol Ther; 1970; 11(6):789-801. PubMed ID: 4921292 [No Abstract] [Full Text] [Related]
34. A double blind study of 1-dopa treatment in Parkinson's disease. Rinne UK; Sonninen V Eur Neurol; 1968; 1(3):180-91. PubMed ID: 4880674 [No Abstract] [Full Text] [Related]
35. [Psychiatric complications of L-Dopa treatment of parkinsonism]. Refsum H Tidsskr Nor Laegeforen; 1973 Apr; 93(10):680-5. PubMed ID: 4755082 [No Abstract] [Full Text] [Related]
36. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports]. Rosati G; Agnetti V; Mura F; Granieri E Minerva Med; 1974 May; 65(33):1811-23. PubMed ID: 4602058 [No Abstract] [Full Text] [Related]
37. Treatment of Parkinson's disease with L-dopa: a current appraisal. Kofman O Can Med Assoc J; 1971 Mar; 104(6):483-7. PubMed ID: 5549988 [TBL] [Abstract][Full Text] [Related]
38. Psychiatric aspects in Parkinsonism treated with L-dopa. Damãsio AR; Lobo-Antunes J; Macedo C J Neurol Neurosurg Psychiatry; 1971 Oct; 34(5):502-7. PubMed ID: 5127432 [TBL] [Abstract][Full Text] [Related]
39. [Psychic manifestations during treatment of Parkinson's disease with L-dopa]. Bonduelle M Rev Neurol (Paris); 1970 Feb; 122(2):140. PubMed ID: 5517897 [No Abstract] [Full Text] [Related]
40. Behavioral effects of l-dopa in man. Goodwin FK Semin Psychiatry; 1971 Nov; 3(4):477-92. PubMed ID: 5173049 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]